Publications

2023

Systematic Literature Review of Quality-of-Life Questionnaires in Waldenström Macroglobulinaemia - Need for a Disease-Specific Tool.

Bristogiannis, Sotirios, Jahanzaib Khwaja, Yadanar Lwin, Encarl Uppal, Shirley D'Sa, and Charalampia Kyriakou.
eJHaem n/a, no. n/a

Plain Language Summary of the Innovate Study: Ibrutinib Plus Rituximab Is Well-Tolerated and Effective in People with Waldenström's Macroglobulinemia

Buske, C., A. Tedeschi, J. Trotman, R. García-Sanz, D. MacDonald, V. Leblond, B. Mahe, C. Herbaux, J. V. Matous, C. S. Tam, L. T. Heffner, M. Varettoni, M. L. Palomba, C. Shustik, E. Kastritis, S. P. Treon, J. Ping, B. Hauns, I. Arango-Hisijara, and M. A. Dimopoulos.
Future Oncol (Feb 23 2023).

Born in the Uk: A Registry to Improve and Broadcast Knowledge on Waldenström Macroglobulinaemia

Durot, E. and A. Delmer.
Br J Haematol (Feb 16 2023).

Patient Preferences Regarding Treatment Options for Waldenström's Macroglobulinemia: A Discrete Choice Experiment

Amaador, K., P. T. Nieuwkerk, M. C. Minnema, M. J. Kersten, and J. M. I. Vos.
Cancer Med 12, no. 3 (Feb 2023): 3376-86.

Patient Reported Outcome Measures in Waldenström Macroglobulinaemia: A Real-World Data Analysis from the Wmuk Rory Morrison Registry

Khwaja, J., E. Uppal, S. Bristogiannis, H. McCarthy, J. Kothari, A. Rismani, H. Scorer, J. Nicholson, D. El-Sharkawi, S. D'Sa, and C. Kyriakou.
EJHaem 4, no. 1 (Feb 2023): 221-25.

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia

A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia
Buske, C., M. A. Dimopoulos, A. Grunenberg, E. Kastritis, C. Tomowiak, B. Mahé, X. Troussard, R. Hajek, A. Viardot, O. Tournilhac, T. Aurran, S. Lepretre, H. Zerazhi, B. Hivert, V. Leblond, S. de Guibert, L. Brandefors, R. Garcia-Sanz, M. Gomes da Silva, E. Kimby, B. Schmelzle, D. Kaszynski, J. Dreyhaupt, R. Muche, and P. Morel.
J Clin Oncol (Feb 10 2023): Jco2201805.

Diagnostics in Waldenström's Macroglobulinemia: A Consensus Statement of the European Consortium for Waldenström's Macroglobulinemia

Dogliotti, I., C. Jiménez, M. Varettoni, D. Talaulikar, T. Bagratuni, M. Ferrante, J. Pérez, D. Drandi, N. Puig, M. Gilestro, M. García-Álvarez, R. Owen, W. Jurczak, A. Tedeschi, V. Leblond, E. Kastritis, M. J. Kersten, S. D'Sa, M. Kaščák, W. Willenbacher, A. M. Roccaro, S. Poulain, P. Morel, C. Kyriakou, F. Fend, J. M. I. Vos, M. A. Dimopoulos, C. Buske, S. Ferrero, and R. García-Sanz.
Leukemia 37, no. 2 (Feb 2023): 388-95.

Bruton Tyrosine Kinase Inhibitors in the Management of Waldenström Macroglobulinemia

Castillo, J. J., C. Buske, J. Trotman, S. Sarosiek, and S. P. Treon.
Am J Hematol 98, no. 2 (Feb 2023): 338-47.

Targeting the Immune Microenvironment in Waldenström Macroglobulinemia Via Halting the Cd40/Cd40-Ligand Axis

Sacco, A., V. Desantis, J. Celay, V. Giustini, F. Rigali, F. D. Savino, M. Cea, D. Soncini, A. Cagnetta, A. G. Solimando, D. D'Aliberti, S. Spinelli, D. Ramazzotti, C. Almici, K. Todoerti, A. Neri, A. Anastasia, A. Tucci, M. Motta, M. Chiarini, Y. Kawano, J. A. Martinez-Climent, R. Piazza, and A. M. Roccaro.
Blood (Feb 3 2023).

Dose of Ibrutinib in Waldenström Macroglobulinaemia: Less Can Be More

Tohidi-Esfahani, I. and J. Trotman.
Br J Haematol (Jan 30 2023).

The Rory Morrison Wmuk Registry for Waldenström Macroglobulinaemia: The Growth of a National Registry for a Rare Disorder

Uppal, E., J. Khwaja, J. Bomsztyk, H. McCarthy, J. Kothari, P. Walton, H. Scorer, C. Kyriakou, D. El-Sharkawi, and S. D'Sa.
Br J Haematol (Jan 25 2023).

Patients with Treated Indolent Lymphomas Immunized with Bnt162b2 Have Reduced Anti-Spike Neutralizing Igg to Sars-Cov-2 Variants, but Preserved Antigen-Specific T Cell Responses

Beaton, B., S. C. Sasson, K. Rankin, J. Raedemaeker, A. Wong, P. Hastak, C. Phetsouphanh, A. Warden, V. Klemm, C. M. L. Munier, A. C. Hoppe, F. Tea, A. Pillay, A. O. Stella, A. Aggarwal, O. Lavee, I. D. Caterson, S. Turville, A. D. Kelleher, F. Brilot, and J. Trotman.
Am J Hematol 98, no. 1 (Jan 2023): 131-39.

Managing Waldenström's Macroglobulinemia with Btk Inhibitors

Buske, C., W. Jurczak, J. E. Salem, and M. A. Dimopoulos.
Leukemia 37, no. 1 (Jan 2023): 35-46.

Waldenström Disease: News and Perspectives in 2022

Bouclet, F., D. Krzisch, V. Leblond, C. Tomowiak, K. Laribi, L. Ysebaert, O. Tournilhac, C. Dartigeas, S. Leprêtre, and L. Jondreville.
Bull Cancer 110, no. 1 (Jan 2023): 88-100.

Treatment of Relapsed and Refractory Waldenstrom Macroglobulinemia

Amaador, K., M. J. Kersten, M. C. Minnema, and J. M. I. Vos.
Leuk Lymphoma 64, no. 1 (Jan 2023): 30-41.

2022

Treatment of Patients with Waldenström Macroglobulinaemia: Clinical Practice Update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Talaulikar, D., D. Joshua, P. J. Ho, J. Gibson, H. Quach, S. Gibbs, S. Ling, C. Ward, B. Augustson, J. Trotman, S. J. Harrison, and C. S. Tam.
Intern Med J (Nov 28 2022).

Clinical Practice Update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Talaulikar, D., D. Joshua, P. J. Ho, J. Gibson, H. Quach, S. Gibbs, S. Ling, C. Ward, B. Augustson, J. Trotman, S. J. Harrison, and C. S. Tam. "Treatment of Patients with Waldenström Macroglobulinaemia:
Intern Med J (Nov 28 2022).

Low Spike Antibody Levels and Impaired Ba.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom's Macroglobulinemia after Bnt162b2 Booster Vaccination

Rosati, M., E. Terpos, J. Bear, R. Burns, S. Devasundaram, I. Ntanasis-Stathopoulos, M. Gavriatopoulou, E. Kastritis, M. A. Dimopoulos, G. N. Pavlakis, and B. K. Felber.
Cancers (Basel) 14, no. 23 (Nov 25 2022).

Waldenström Macroglobulinemia Whole Genome Reveals Prolonged Germinal Center Activity and Late Copy Number Aberrations

Maclachlan, K. H., T. Bagratuni, E. Kastritis, B. Ziccheddu, S. X. Lu, V. Yellapantula, C. A. Famulare, K. V. Argyropoulos, A. Derkach, E. Papaemmanuil, A. Dogan, A. M. Lesokhin, S. Z. Usmani, O. Landgren, M. L. Palomba, F. Maura, and M. A. Dimopoulos.
Blood Adv (Nov 4 2022).

Bortezomib-Based Therapy Is Effective and Well Tolerated in Frontline and Multiply Pre-Treated Waldenström Macroglobulinaemia Including Btki Failures: A Real-World Analysis

Khwaja, J., E. Uppal, R. Baker, K. Trivedi, A. Rismani, R. Gupta, I. Proctor, C. Kyriakou, and S. D'Sa.
EJHaem 3, no. 4 (Nov 2022): 1330-34.

Inflammation in Waldenström MacroglobulinAssociated with 6q Deletion and Need for Treatment Initiation

Forgeard, N., M. Baron, J. Caron, C. Boccon-Gibod, D. Krzisch, N. Guedes, V. Morel, N. Jacque, M. Ouzegdouh, S. Choquet, C. Bravetti, F. Nguyen-Khac, E. Chapiro, V. Leblond, and D. Roos-Weil.
Haematologica 107, no. 11 (Nov 1 2022): 2720-24.

Molecular Remission Is an Independent Predictor of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Chemo-Immunotherapy: Results from the Fil_Biowm Study

Varettoni, M., S. Zibellini, M. Merli, D. Drandi, C. Jiménez, D. Furlan, V. V. Ferretti, N. Fabbri, I. Dogliotti, C. Varraso, M. Ferrante, E. Cappello, V. Peri, C. Cavalloni, M. Borriero, G. V. Facchetti, S. Ferrero, L. Arcaini, and R. Garcia-Sanz.
Hematol Oncol (Oct 11 2022).

Sars-Cov-2 Humoral Responses Following Booster Bnt162b2 Vaccination in Patients with B-Cell Malignancies

Terpos, E., D. Fotiou, V. Karalis, I. Ntanasis-Stathopoulos, A. D. Sklirou, M. Gavriatopoulou, P. Malandrakis, V. A. Iconomidou, E. Kastritis, I. P. Trougakos, and M. A. Dimopoulos.
Am J Hematol 97, no. 10 (Oct 2022): 1300-08.

Pooled Safety Analysis of Zanubrutinib Monotherapy in Patients with B-Cell Malignancies. Blood Adv. 2022;6(4):1296-1308

Tam Cs, Dimopoulos M, Garcia-Sanz R, Et al.
Blood Adv 6, no. 17 (Sep 13 2022): 4983.

Therapeutic Activation of G Protein-Coupled Estrogen Receptor 1 in Waldenström Macroglobulinemia

Morelli, E., Z. R. Hunter, M. Fulciniti, A. Gullà, I. D. Perrotta, V. Zuccalà, C. Federico, G. Juli, M. Manzoni, D. Ronchetti, E. Romeo, M. E. Gallo Cantafio, D. Soncini, L. Maltese, M. Rossi, A. M. Roccaro, M. Cea, P. Tassone, A. Neri, S. C. Treon, N. C. Munshi, G. Viglietto, and N. Amodio.
Exp Hematol Oncol 11, no. 1 (Sep 12 2022): 54.

Igm Monoclonal Gammopathies of Clinical Significance: Diagnosis and Management

Khwaja, J., S. D'Sa, M. C. Minnema, M. J. Kersten, A. Wechalekar, and J. M. Vos.
Haematologica 107, no. 9 (Sep 1 2022): 2037-50.

Use of Btk Inhibitors with Special Focus on Ibrutinib in Waldenström Macroglobulinemia: An Expert Panel Opinion Statement

Ferrero, S., M. Gentile, L. Laurenti, F. R. Mauro, M. Martelli, P. Sportoletti, C. Visco, P. L. Zinzani, A. Tedeschi, and M. Varettoni.
Hematol Oncol 40, no. 3 (Aug 2022): 332-40.

Does Early Disease Progression Predict Survival after First Line-Treatment of Waldenström Macroglobulinemia?

Labreuche, J., D. Assouan, E. Durot, C. Tomowiak, D. Roos-Weil, E. Toussaint, F. Bijou, R. Lemal, A. Brion, K. Laribi, L. Ysebaert, A. Duhamel, and P. Morel.
Hematol Oncol 40, no. 3 (Aug 2022): 400-08.

Serum Neurofilament Light Chain, Contactin-1 and Complement Activation in Anti-Mag Igm Paraprotein-Related Peripheral Neuropathy

Amaador, K., L. Wieske, M. J. A. Koel-Simmelink, A. Kamp, I. Jongerius, K. de Heer, C. E. Teunissen, M. C. Minnema, N. C. Notermans, F. Eftimov, M. J. Kersten, and J. M. I. Vos.
J Neurol 269, no. 7 (Jul 2022): 3700-05.

Dutch Physician's Perspectives on Diagnosis and Treatment of Waldenström's Macroglobulinemia before and after the Implementation of a National Guideline.

Amaador, K., M. J. Kersten, M. C. Minnema, and J. M. I. Vos.
Hemasphere 6, no. 7 (Jul 2022): e746.

High Frequency of Central Nervous System Involvement in Transformed Waldenström Macroglobulinemia

Durot, E., L. Kanagaratnam, S. Zanwar, E. Toussaint, E. Kastritis, S. D'Sa, M. Alcoceba, C. Tomowiak, B. Hivert, C. Protin, J. P. Abeykoon, J. M. I. Vos, A. S. Michallet, C. Rodier, J. Dupuis, S. Leprêtre, F. Merabet, X. Roussel, J. M. Zini, C. Regny, A. Patel, P. Morel, D. Roos-Weil, S. P. Treon, M. A. Dimopoulos, R. Garcia-Sanz, P. Kapoor, J. J. Castillo, and A. J. Delmer.
Blood Adv 6, no. 12 (Jun 28 2022): 3655-58.

T-Cell Subset Composition and Functionality in Patients with Waldenström's Macroglobulinemia

Amaador, K., A. Martens, R. de Boer, J. Rietveld, M. Heemskerk, C. E. Rutten, E. Eldering, M. J. Kersten, A. P. Kater, J. Vos, and S. Tonino.
Leuk Lymphoma 63, no. 6 (Jun 2022): 1469-73.

Mast Cell Density and Its Clinical Relevance in Waldenström's Macroglobulinemia

Lemal, R., S. Poulain, A. Ledoux-Pilon, L. Veronese, A. Tchirkov, B. Lebecque, T. Tassin, J. O. Bay, F. Charlotte, F. Nguyen-Khac, M. Berger, C. Godfraind, L. Ysebaert, F. Davi, B. Pereira, V. Leblond, O. Hermine, R. Guièze, F. Pagès, and O. Tournilhac.
EJHaem 3, no. 2 (May 2022): 371-78.

A Phase-Ii Study of Atezolizumab in Combination with Obinutuzumab or Rituximab for Relapsed or Refractory Mantle Cell or Marginal Zone Lymphoma or Waldenström's Macroglobulinemia

Panayiotidis, P., G. Tumyan, C. Thieblemont, V. V. Ptushkin, A. Marin-Niebla, R. García-Sanz, S. Le Gouill, A. Stathis, A. Bottos, H. Hamidi, P. Katz, T. Perretti, J. C. Willis, and C. Buske.
Leuk Lymphoma 63, no. 5 (May 2022): 1058-69.

Myd88 Mutations: Transforming the Landscape of Igm Monoclonal Gammopathies.

Alcoceba, M., M. García-Álvarez, A. Medina, R. Maldonado, V. González-Calle, M. C. Chillón, M. E. Sarasquete, M. González, R. García-Sanz, and C. Jiménez. Int J Mol Sci 23, no. 10 (May 16 2022).

Response to Vaccination against Sars-Cov-2 in 168 Patients with Waldenström Macroglobulinaemia: A French Innovative Leukaemia Organization Study

Tomowiak, C., V. Leblond, K. Laribi, M. Baron, C. Puppinck, P. Gérard, E. Courret, G. Gorochov, D. Sterlin, O. Tournilhac, P. Morel, F. Cymbalista, and D. Roos-Weil.
Br J Haematol 197, no. 4 (May 2022): 424-27.

Low Neutralizing Antibody Responses in Wm, Cll and Nhl Patients after the First Dose of the Bnt162b2 and Azd1222 Vaccine

Gavriatopoulou, M., E. Terpos, E. Kastritis, A. Briasoulis, S. Gumeni, I. Ntanasis-Stathopoulos, A. D. Sklirou, P. Malandrakis, E. Eleutherakis-Papaiakovou, M. Migkou, I. P. Trougakos, and M. A. Dimopoulos.
Clin Exp Med 22, no. 2 (May 2022): 319-23.

Managing Hematological Cancer Patients During the Covid-19 Pandemic: An esmo-Eha Interdisciplinary Expert Consensus

Buske, C., M. Dreyling, A. Alvarez-Larrán, J. Apperley, L. Arcaini, C. Besson, L. Bullinger, P. Corradini, M. Giovanni Della Porta, M. Dimopoulos, S. D'Sa, H. T. Eich, R. Foà, P. Ghia, M. G. da Silva, J. Gribben, R. Hajek, C. Harrison, M. Heuser, B. Kiesewetter, J. J. Kiladjian, N. Kröger, P. Moreau, J. R. Passweg, F. Peyvandi, D. Rea, J. M. Ribera, T. Robak, J. F. San-Miguel, V. Santini, G. Sanz, P. Sonneveld, M. von Lilienfeld-Toal, C. Wendtner, G. Pentheroudakis, and F. Passamonti.
ESMO Open 7, no. 2 (Apr 2022): 100403.

Diagnosis and Management of Waldenström Macroglobulinaemia-a British Society for Haematology Guideline

Pratt, G., D. El-Sharkawi, J. Kothari, S. D'Sa, R. Auer, H. McCarthy, R. Krishna, O. Miles, C. Kyriakou, and R. Owen.
Br J Haematol 197, no. 2 (Apr 2022): 171-87.

Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and Igm-Mgus: Current Insights and Clinical Relevance

Drandi, D., P. Decruyenaere, M. Ferrante, F. Offner, J. Vandesompele, and S. Ferrero.
Diagnostics (Basel) 12, no. 4 (Apr 12 2022).

Conditional Relative Survival in Waldenström's Macroglobulinaemia: A Population-Based Study in the Netherlands

Amaador, K., M. J. Kersten, O. Visser, E. F. M. Posthuma, M. C. Minnema, J. M. I. Vos, and A. G. Dinmohamed.
Br J Haematol 196, no. 5 (Mar 2022): 1205-08.

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

Minson, A., C. Tam, M. Dickinson, and J. F. Seymour.
Cancers (Basel) 14, no. 5 (Mar 1 2022).

Preneoplastic Somatic Mutations Including Myd88(L265p) in Lymphoplasmacytic Lymphoma

Rodriguez, S., J. Celay, I. Goicoechea, C. Jimenez, C. Botta, M. J. Garcia-Barchino, J. J. Garces, M. Larrayoz, S. Santos, D. Alignani, A. Vilas-Zornoza, C. Perez, S. Garate, S. Sarvide, A. Lopez, H. C. Reinhardt, Y. R. Carrasco, I. Sanchez-Garcia, M. J. Larrayoz, M. J. Calasanz, C. Panizo, F. Prosper, J. M. Lamo-Espinosa, M. Motta, A. Tucci, A. Sacco, M. Gentile, S. Duarte, H. Vitoria, C. Geraldes, A. Paiva, N. Puig, R. Garcia-Sanz, A. M. Roccaro, G. Fuerte, J. F. San Miguel, J. A. Martinez-Climent, and B. Paiva.
Sci Adv 8, no. 3 (Jan 21 2022): eabl4644.

Determination of Myd88l265p Mutation Fraction in Igm Monoclonal Gammopathies.

Bagratuni, T., A. Markou, D. Patseas, N. Mavrianou-Koutsoukou, F. Aktypi, C. I. Liacos, A. D. Sklirou, F. Theodorakakou, I. Ntanasis-Stathopoulos, M. Gavriatopoulou, I. P. Trougakos, E. Lianidou, E. Terpos, E. Kastritis, and M. A. Dimopoulos.
Blood Adv 6, no. 1 (Jan 11 2022): 189-99.

Combining Ixazomib with Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/Ii Hovon124/Ecwm-R2 Study

Kersten, M. J., K. Amaador, M. C. Minnema, J. M. I. Vos, K. Nasserinejad, M. Kap, E. Kastritis, M. Gavriatopoulou, W. Kraan, M. E. D. Chamuleau, D. Deeren, L. W. Tick, J. K. Doorduijn, F. Offner, L. H. Böhmer, R. D. Liu, S. T. Pals, and M. A. Dimopoulos.
J Clin Oncol 40, no. 1 (Jan 1 2022): 40-51.

Flow Cytometry Detection of Cd138 Expression Continuum between Monotypic B and Plasma Cells Is Associated with Both High Igm Peak Levels and Myd88 Mutation and Contributes to Diagnosis of Waldenström Macroglobulinemia

Gayet, M., V. Leymarie, P. Derouault, E. Guérin, J. Vaidié, V. Pascal, M. Boulin, N. Dmytruk, J. Chauzeix, F. Trimoreau, N. Gachard, J. Feuillard, and D. Rizzo.
Cytometry B Clin Cytom 102, no. 1 (Jan 2022): 62-69.

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis from the Randomized Phase Iii Innovate Study

2021

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate Trial

Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey V Matous, David MacDonald, Constantine S Tam, Olivier Tournilhac, Shuo Ma, Steven P Treon, Albert Oriol, Jerry Ping, Eva M Briso, Israel Arango-Hisijara, Meletios A Dimopoulos

Obinutuzumab and Idelalisib in Symptomatic Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Tomowiak, C., S. Poulain, C. Herbaux, A. Perrot, B. Mahé, P. Morel, T. Aurran, O. Tournilhac, S. Leprêtre, S. Assaad, B. Villemagne, O. Casasnovas, D. Nollet, D. Roos-Weil, S. Chevret, and V. Leblond.
Blood Adv 5, no. 9 (May 11 2021): 2438-46.

Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia

Lisa Marie Kaiser, Mirja Harms, Daniel Sauter, Vijay P S Rawat, Mirco Glitscher, Eberhard Hildt, Daniel Tews, Zachary Hunter, Jan Münch, Christian Buske

CXCR4 in Waldenström's Macroglobulinema: chances and challenges

Lisa Marie Kaiser, Zachary R Hunter, Steven P Treon, Christian Buske

2020

Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial

Meletios Dimopoulos, Ramon Garcia Sanz, Hui-Peng Lee, Marek Trneny, Marzia Varettoni, Stephen Opat, Shirley D'Sa, Roger G Owen, Gavin Cull, Stephen Mulligan, Jaroslaw Czyz, Jorge J Castillo, Marina Motta, Tanya Siddiqi, Mercedes Gironella Mesa, Miquel Granell Gorrochategui, Dipti Talaulikar, Pier Luigi Zinzani , Elham Askari, Sebastian Grosicki, Albert Oriol, Simon Rule, Janusz Kloczko, Alessandra Tedeschi, Christian Buske, Veronique Leblond, Judith Trotman, Wai Y Chan, Jan Michel, Jingjing Schneider, Ziwen Tan, Aileen Cohen, Jane Huang, Constantine S Tam

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

Jorge J Castillo, Ranjana H Advani, Andrew R Branagan, Christian Buske, Meletios A Dimopoulos, Shirley D'Sa, Marie José Kersten, Veronique Leblond, Monique C Minnema, Roger G Owen, M Lia Palomba, Dipti Talaulikar, Alessandra Tedeschi, Judith Trotman, Marzia Varettoni, Josephine M Vos, Steven P Treon, Efstathios Kastritis

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Constantine S Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G Owen, Paula Marlton, Björn E Wahlin, Ramón Garcia Sanz, Helen McCarthy, Stephen Mulligan, Alessandra Tedeschi, Jorge J Castillo, Jaroslaw Czyz, Carlos Fernández de Larrea, David Belada, Edward Libby, Jeffrey V Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trneny, Monique C Minnema, Christian Buske, Veronique Leblond, Judith Trotman, Wai Y Chan, Jingjing Schneider, Sunhee Ro, Aileen Cohen, Jane Huang, Meletios Dimopoulos

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

Dipti Talaulikar, Ranjana H Advani, Andrew R Branagan, Christian Buske, Meletios A Dimopoulos, Shirley D'Sa, Maria J Kersten, Veronique Leblond, Monique C Minnema, Roger G Owen, Maria Lia Palomba, Alessandra Tedeschi, Judith Trotman, Marzia Varettoni, Josephine M Vos, Steven P Treon, Efstathios Kastritis, Jorge J Castillo

Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia

Christian Buske

2019

2018

Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO).

Laribi K, Poulain S, Willems L, Merabet F, Le Calloch R, Eveillard JR, Herbaux C, Roos-Weil D, Chaoui D, Roussel X, Tricot S, Dupuis J, Dartigeas C, Bareau B, Bene MC, Baugier de Materre A, Leblond V.

How I treat rituximab refractory patients with WM.

Gavriatopoulou M, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C.

Ibrutinib for the treatment of Bing-Neel syndrome: A multicenter study.

Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP.

iNNOVATE Follow-up data on efficacy and safety of ibrutinib in treatment naïve and relapsed patients with WM orally presented at this year’s ASH in San Diego

IWWM10 - New York - 2018

We thank Steven Treon and his team for organizing the fantastic IWWM10 in New York in October this year. A great meeting and motivation for all of us to continue our efforts to improve treatment of WM

Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.

Dimopoulos MA, Salman Z, Buske C.

Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study.

Brandefors L, Melin B, Lindh J, Lundqvist K, Kimby E.

Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Kastritis E, Leblond V, Dimopoulos MA, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee.

A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.

Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, Cohen A, Huang J, Buske C.

Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM.

Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, Papasotiriou I, Fotiou D, Migkou M, Roussou M, Kanellias N, Ziogas D, Dialoupi I, Eleutherakis Papaiakovou E, Kastritis E, Dimopoulos MA.

Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.

Bagratuni T, Ntanasis-Stathopoulos I, Gavriatopoulou M, Mavrianou-Koutsoukou N, Liacos C, Patseas D, Kanellias N, Migkou M, Ziogas DC, Eleutherakis-Papaiakovou E, Roussou M, Fotiou D, Terpos E, Kastritis E, Dimopoulos MA.

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.

Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, Dimopoulos MA; European Consortium for Waldenström's Macroglobulinemia.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.

Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia.

Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel.

D'Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastritis E, Laane E, Leblond V, Merlini G, Treon SP, Vos JM, Lunn MP.

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.

Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia.

How we manage patients with Waldenström macroglobulinaemia.

Simon L, Baron M, Leblond V.

2017

Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).

Durot E, Tomowiak C, Michallet AS, Dupuis J, Hivert B, Leprêtre S, Toussaint E, Godet S, Merabet F, Van Den Neste E, Ivanoff S, Roussel X, Zini JM, Regny C, Lemal R, Sutton L, Perrot A, Le Dû K, Kanagaratnam L, Morel P, Leblond V, Delmer A.

Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.

Gavriatopoulou M, Kastritis E, Kyrtsonis MC, Vassilakopoulos TP, Roussou M, Fotiou D, Migkou M, Mpakiri M, Tasidou A, Terpos E, Dimopoulos MA.

Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.

Minnema MC, Kimby E, D'Sa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis E, Kremer S, Fitsiori A, Simon L, Davi F, Lunn M, Castillo JJ, Patterson CJ, Le Garff-Tavernier M, Costopoulos M, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP.

2016

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.

Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, Wechalekar A, Patterson CJ, Treon SP, Dimopoulos MA.

2015

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.

Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A, Vervessou E, Katodritou E, Gika D, Terpos E, Dimopoulos MA.

Ibrutinib in previously treated Waldenström´s macroglobulinemia.

Treon SP1, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL,Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH.

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

Dimopoulos MA1, Kastritis E1, Owen RG2, Kyle RA3, Landgren O4, Morra E5, Leleu X6, García-Sanz R7, Munshi N8, Anderson KC8, Terpos E1, Ghobrial IM8,Morel P9, Maloney D10, Rummel M11, Leblond V12, Advani RH13, Gertz MA3, Kyriakou C14, Thomas SK15, Barlogie B16, Gregory SA17, Kimby E18, Merlini G19,Treon SP8.

Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia.

Tedeschi A, Picardi P, Ferrero S, Benevolo G, Margiotta Casaluci G, Varettoni M, Baratè C, Motta M, Gini G, Goldaniga MC, Visco C, Zaja F, Belsito Petrizi V, Ravelli E, Gentile M, Urbano MA, Franceschetti S, Ghione P, Orsucci L, Frustaci AM, Gaidano G, Vitolo U, Morra E.